A microdose cocktail and population pharmacokinetic study suggests potentially reduced CYP3A and P-gp activities in type 2 diabetes
Yafen Li, Jin Yang, Enda Zhou, Kuo Geng, Zihan Lei, Xueting Yao, Feifei Feng, Yuyan Jin, Weijie Kong, Yiyi Hu, Hao Liang, Haiyan Li, Guo-Ping Yang, Tianpei Hong, Dongyang Liu · 2026
Read A microdose cocktail and population pharmacokinetic study suggests potentially reduced CYP3A and P-gp activities in type 2 diabetes by Yafen Li, Jin Yang, Enda Zhou, Kuo Geng, Zihan Lei, Xueting Yao, Feifei Feng, Yuyan Jin, Weijie Kong, Yiyi Hu, Hao Liang, Haiyan Li, Guo-Ping Yang, Tianpei Hong, Dongyang Liu (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13561922.txt.
Description
Yafen Li and a large team of co-authors check whether type 2 diabetes changes how the body handles drugs in this 2026 study. Patients with diabetes often respond oddly to medicines, hinting that their drug-processing enzymes and transporters work at different speeds. The team measured several of these directly.
Volunteers and patients took tiny single doses of five probe drugs, each tied to a known pathway. Blood modeling suggested two pathways ran slower in diabetes, by roughly a quarter, while two others were unchanged. Gut bacteria levels helped explain one change, and genes and sex explained more of the spread. The results flag which drug classes deserve closer watch in diabetes care.
Catalog record
| CREATOR | Yafen Li, Jin Yang, Enda Zhou, Kuo Geng, Zihan Lei, Xueting Yao, Feifei Feng, Yuyan Jin, Weijie Kong, Yiyi Hu, Hao Liang, Haiyan Li, Guo-Ping Yang, Tianpei Hong, Dongyang Liu |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 40 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |